READ MORE DILANTIN SJS LEGAL NEWS
"It is a test that identifies people who are at high risk of having a nasty reaction to a particular drug used in the treatment of epilepsy," said Dr. Gianpiero Cavalleri, the leader of the Irish group conducting the research.
Cavalleri added that approximately one in 20 patients will have a negative reaction to carbamazepine, which is one of the most common epilepsy treatments in the world.
Some patients suffering the side effects of such medications can develop Stevens-Johnson Syndrome, which is a skin disorder that could take between two and six weeks to treat, according to the National Center for Biotechnology Information.